



PB 136 of 2023

National Health (Minimum Stockholding) Amendment Determination (No. 4) 2023

I, Nikolai Tsyganov, as delegate of the Minister for Health and Aged Care, make the following determination.

Dated 15 December 2023

Nikolai Tsyganov
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health and Aged Care

Contents

1 Name.....	1
2 Commencement	1
3 Authority.....	1
4 Schedules.....	1
Schedule 1—Amendments commencing 1 January 2024	2
<i>National Health (Minimum Stockholding) Determination 2023</i>	2
Schedule 2—Amendments commencing 1 February 2024	7
<i>National Health (Minimum Stockholding) Determination 2023</i>	7
Schedule 3—Amendments commencing 1 April 2024	9
<i>National Health (Minimum Stockholding) Determination 2023</i>	9

1 Name

- (1) This instrument is the *National Health (Minimum Stockholding) Amendment Determination (No. 4) 2023*.
- (2) This instrument may also be cited as PB 136 of 2023.

2 Commencement

- (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information		
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table	1 January 2024.	1 January 2024
2. Schedule 1	1 January 2024.	1 January 2024
3. Schedule 2	1 February 2024.	1 February 2024
4. Schedule 3	1 April 2024.	1 April 2024

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

- (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 99AEKC(2) of the *National Health Act 1953*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments commencing 1 January 2024

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

Baclofen	After: Tablet 10 mg	Oral	APO-Baclofen	3 months stock by reference to usual demand
Bisoprolol	insert: Tablet containing bisoprolol fumarate 10 mg	Oral	Bisoprolol Dr.Reddy's	between 1 January 2024 and 29 February 2024— 0 months stock by reference to usual demand
Bisoprolol	Tablet containing bisoprolol fumarate 2.5 mg	Oral	Bisoprolol Dr.Reddy's	between 1 January 2024 and 29 February 2024— 0 months stock by reference to usual demand
Bisoprolol	Tablet containing bisoprolol fumarate 5 mg	Oral	Bisoprolol Dr.Reddy's	between 1 January 2024 and 29 February 2024— 0 months stock by reference to usual demand

2 Schedule 1 (table)

Ezetimibe with simvastatin	After: Tablet 10 mg-10 mg	Oral	APO-Ezetimibe/Simvastatin 10/10	3 months stock by reference to usual demand
Ezetimibe with simvastatin	insert: Tablet 10 mg-10 mg	Oral	EZESIM 10/10	between 1 January 2024 and 29 February 2024— 0 months stock by reference to usual demand

3 Schedule 1 (table)

Ezetimibe with simvastatin	After: Tablet 10 mg-20 mg	Oral	APO-Ezetimibe/Simvastatin 10/20	3 months stock by reference to usual demand
Ezetimibe with simvastatin	insert: Tablet 10 mg-20 mg	Oral	EZESIM 10/20	between 1 January 2024 and 29 February 2024— 0 months stock by reference to usual demand

demand

4 Schedule 1 (table)

	After:				
Ezetimibe with simvastatin	Tablet 10 mg-40 mg	Oral	APO-Ezetimibe/Simvastatin 10/40	3 months stock by reference to usual demand	
	insert:				
Ezetimibe with simvastatin	Tablet 10 mg-40 mg	Oral	EZESIM 10/40	between 1 January 2024 and 29 February 2024— 0 months stock by reference to usual demand	

5 Schedule 1 (table)

	After:			
Ezetimibe with simvastatin	Tablet 10 mg-80 mg	Oral	APO-Ezetimibe/Simvastatin 10/80	3 months stock by reference to usual demand
	insert:			
Ezetimibe with simvastatin	Tablet 10 mg-80 mg	Oral	EZESIM 10/80	between 1 January 2024 and 29 February 2024— 0 months stock by reference to usual demand

6 Schedule 1 (table)

	After:			
Fentanyl	Transdermal patch 8.4 mg	Transdermal	APO-Fentanyl	3 months stock by reference to usual demand
	insert:			
Filgrastim	Injection 300 micrograms in 1 mL	Injection	Neupogen	between 1 January 2024 and 29 February 2024— 0 months stock by reference to usual demand
Filgrastim	Injection 480 micrograms in 1.6 mL	Injection	Neupogen	between 1 January 2024 and 29 February 2024— 0 months stock by reference to usual demand

7 Schedule 1 (table)

Gemfibrozil	After: Tablet 600 mg	Oral	Lipigem	between 1 July 2023 and 31 December 2023—2 months stock by reference to usual demand
Glimepiride	insert: Tablet 1 mg	Oral	Aylide 1	between 1 January 2024 and 31 March 2024—0 months stock by reference to usual demand

8 Schedule 1 (table)

Glimepiride	After: Tablet 2 mg	Oral	Amaryl	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Glimepiride	insert: Tablet 2 mg	Oral	Aylide 2	between 1 January 2024 and 31 March 2024—0 months stock by reference to usual demand

9 Schedule 1 (table)

Glimepiride	After: Tablet 3 mg	Oral	Amaryl	Between 1 October 2023 and 31 December 2023—0 months stock by reference to usual demand
Glimepiride	insert: Tablet 3 mg	Oral	Aylide 3	between 1 January 2024 and 31 March 2024—0 months stock by reference to usual demand
Glimepiride	Tablet 4 mg	Oral	Aylide 4	between 1 January 2024 and 31 March 2024—0 months stock by reference to usual demand

10 Schedule 1 (table)

Latanoprost	After: Eye drops 50 micrograms per mL, 2.5 mL	Application to the Eye	APO-Latanoprost	2 months stock by reference to usual demand
Levetiracetam	insert: Tablet 1 g	Oral	Levecetam 1000	between 1 January 2024 and 29 February 2024—0 months stock by reference to usual demand
Levetiracetam	Tablet 250 mg	Oral	Levecetam 250	between 1 January 2024 and 29 February 2024—0 months stock by reference to usual demand
Levetiracetam	Tablet 500 mg	Oral	Levecetam 500	between 1 January 2024 and 29 February 2024—0 months stock by reference to usual demand

11 Schedule 1 (table)

Lithium	After: Tablet containing lithium carbonate 450 mg (slow release)	Oral	Quilonum SR	after 30 November 2023—6 months stock by reference to usual PBS demand
Macrogol 3350	insert: Oral liquid 13.125 g in 25 mL with electrolytes, 500 mL	Oral	Movicol Liquid	between 1 January 2024 and 30 April 2024—0 months stock by reference to usual demand

12 Schedule 1 (table)

Salbutamol	After: Nebuliser solution 5 mg (as sulfate) in 2.5 mL single dose units, 30	Inhalation	Salbutamol AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Salbutamol	insert: Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC-free formulation)	Inhalation by Mouth	Asmol CFC-Free with dose counter	between 1 January 2024 and 30 June 2024—0 months stock by reference to usual demand
Salbutamol	Pressurised inhalation 100	Inhalation by Mouth	Zempreon CFC-Free with dose counter	between 1 January 2024 and 30 June

micrograms (as sulfate) per dose with dose counter, 200 doses (CFC-free formulation)

2024—0 months stock by reference to usual demand

13 Schedule 1 (table)

Tacrolimus	After: Capsule 5 mg	Oral	Tacrograf	3 months stock by reference to usual demand
Telmisartan	insert: Tablet 40 mg	Oral	Telmisartan-DRLA	between 1 January 2024 and 29 February 2024—0 months stock by reference to usual demand
Telmisartan	Tablet 80 mg	Oral	Telmisartan-DRLA	between 1 January 2024 and 29 February 2024—0 months stock by reference to usual demand

14 Schedule 1 (table)

Valproic acid	After: Tablet, crushable, containing sodium valproate 100 mg	Oral	Epilim	4 months stock by reference to usual PBS demand
Vinorelbine	insert: Solution for I.V. infusion 10 mg (as tartrate) in 1 mL	Injection	Navelbine	between 1 January 2024 and 31 March 2024—0 months stock by reference to usual demand

Schedule 2—Amendments commencing 1 February 2024

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

Acarbose	Before:	Tablet 100 mg	Oral	GLYBOSAY	2 months stock by reference to usual demand
Acarbose	insert:	Tablet 100 mg	Oral	Acarbose Viatris	4 months stock by reference to usual demand of both Acarbose Viatris and Acarbose Mylan added together

2 Schedule 1 (table)

Bosentan	After:	Tablet 125 mg (as monohydrate)	Oral	Bosentan APO	3 months stock by reference to usual demand
Bosentan	insert:	Tablet 125 mg (as monohydrate)	Oral	Bosentan Cipla	between 1 February 2024 and 31 July 2024—0 months stock by reference to usual demand

3 Schedule 1 (table)

Pregabalin	After:	Capsule 150 mg	Oral	LYPRALIN	between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Pregabalin	insert:	Capsule 25 mg	Oral	Cipla Pregabalin	between 1 February 2024 and 31 July 2024—0 months stock by reference to usual demand

4 Schedule 1 (table)

Pregabalin	After: Capsule 25 mg	Oral	Pregabalin Lupin	4 months stock by reference to usual demand of both Pregabalin Lupin and Pregabalin GH added together
Pregabalin	insert: Capsule 300 mg	Oral	Cipla Pregabalin	between 1 February 2024 and 31 July 2024—0 months stock by reference to usual demand

5 Schedule 1 (table)

Pregabalin	After: Capsule 300 mg	Oral	Pregabalin Lupin	4 months stock by reference to usual demand of both Pregabalin Lupin and Pregabalin GH added together
Pregabalin	insert: Capsule 75 mg	Oral	Cipla Pregabalin	between 1 February 2024 and 31 July 2024—0 months stock by reference to usual demand

6 Schedule 1 (table)

Mitozantrone	Omit: Injection 25 mg (as hydrochloride) in 12.5 mL	Injection	Onkotrone	between 1 December 2023 and 29 February 2024—0 months stock by reference to usual demand
--------------	--	-----------	-----------	--

7 Schedule 1 (table)

Thiamine	After: Tablet containing thiamine hydrochloride 100 mg	Oral	Betavit	4 months stock by reference to usual PBS demand
Tobramycin	insert: Injection 80 mg in 2 mL	Injection	Tobramycin Viartis	4 months stock by reference to usual demand of both Tobramycin Viartis and Tobramycin Mylan added together

Schedule 3—Amendments commencing 1 April 2024

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

Amphotericin B	After: Lozenge 10 mg	Oral	Fungilin	4 months stock by reference to usual PBS demand
Anakinra	insert: Injection 100 mg in 0.67 mL single use pre-filled syringe	Injection	Kineret	6 months stock by reference to usual PBS demand

2 Schedule 1 (table)

Baclofen	After: Tablet 10 mg	Oral	APO-Baclofen	3 months stock by reference to usual demand
Benzathine benzylpenicillin	insert: Injection containing 1,200,000 units benzathine benzylpenicillin tetrahydrate in 2.3 mL single use pre-filled syringe	Injection	Bicillin L-A	6 months stock by reference to usual PBS demand
Benzathine benzylpenicillin	Injection containing 600,000 units benzathine benzylpenicillin tetrahydrate in 1.17 mL single use pre-filled syringe	Injection	Bicillin L-A	6 months stock by reference to usual PBS demand

3 Schedule 1 (table)

Diltiazem	After: Tablet containing diltiazem hydrochloride 60 mg	Oral	Diltiazem AN	between 1 December 2023 and 31 January 2024—0 months stock by reference to usual demand
Diphtheria and tetanus vaccine, adsorbed, diluted for adult use	insert: Injection 0.5 mL in pre-filled syringe	Injection	ADT Booster	6 months stock by reference to usual PBS demand

4 Schedule 1 (table)

Metoprolol	After: Tablet containing metoprolol tartrate 50 mg	Oral	Metrol 50	between 1 July 2023 and 31 December 2023—5.5 months
------------	---	------	-----------	---

					stock by reference to usual demand
Metronidazole	insert: Suppositories 500 mg, 10	Rectal	Flagyl		6 months stock by reference to usual PBS demand
Milk protein and fat formula with vitamins and minerals -- carbohydrate free	Oral powder 225 g (Carbohydrate Free Mixture)	Oral	Carbohydrate Free Mixture		6 months stock by reference to usual PBS demand

5 Schedule 1 (table)

Permethrin	After: Cream 50 mg per g, 30 g	Application	Lyclear		after 30 November 2023—6 months stock by reference to usual PBS demand
Pimecrolimus	insert: Cream 10 mg per g, 15 g	Application	Elidel		6 months stock by reference to usual PBS demand

6 Schedule 1 (table)

Pregabalin	After: Capsule 150 mg	Oral	LYPRALIN		between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Pregabalin	insert: Capsule 150 mg	Oral	Pregabalin Lupin		4 months stock by reference to usual demand of both Pregabalin Lupin and Pregabalin GH added together

7 Schedule 1 (table)

Pregabalin	After: Capsule 75 mg	Oral	LYPRALIN		between 1 November 2023 and 31 December 2023—0 months stock by reference to usual demand
Pregabalin	insert: Capsule 75 mg	Oral	Pregabalin Lupin		4 months stock by reference to usual demand of both Pregabalin Lupin and Pregabalin GH added together

8 Schedule 1 (table)

Probenecid	After: Tablet 500 mg	Oral	Pro-Cid	after 30 November 2023—6 months stock by reference to usual PBS demand
Prochlorperazine	insert: Injection containing prochlorperazine mesilate 12.5 mg in 1 mL	Injection	Stemetil	6 months stock by reference to usual PBS demand
Protein hydrolysate formula with medium chain triglycerides	Oral powder 450 g (Aptamil Gold+ Pepti-Junior)	Oral	Aptamil Gold+ Pepti-Junior	6 months stock by reference to usual PBS demand

9 Schedule 1 (table)

Valproic acid	Omit: Oral liquid containing sodium valproate 200 mg per 5 mL, 300 mL	Oral	Epilim Liquid	4 months stock by reference to usual PBS demand
Valproic acid	substitute: Oral liquid containing sodium valproate 200 mg per 5 mL, 300 mL	Oral	Epilim Liquid	6 months stock by reference to usual PBS demand

10 Schedule 1 (table)

Valproic acid	Omit: Oral solution containing sodium valproate 200 mg per 5 mL, 300 mL	Oral	Epilim Syrup	4 months stock by reference to usual PBS demand
Valproic acid	substitute: Oral solution containing sodium valproate 200 mg per 5 mL, 300 mL	Oral	Epilim Syrup	6 months stock by reference to usual PBS demand